# Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

> **NCT01327612** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 12 (actual)

## Conditions studied

- Advanced Solid Tumors
- Carcinoid
- Colorectal Cancer
- Locally Advanced
- Lymphoma
- Metastatic Cancer
- Non-Small Cell Lung Cancer
- Sarcoma
- Solid Tumors

## Interventions

- **DRUG:** Modified FOLFOX6
- **BIOLOGICAL:** Conatumumab
- **BIOLOGICAL:** Ganitumab
- **BIOLOGICAL:** Bevacizumab

## Key facts

- **NCT ID:** NCT01327612
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-03
- **Primary completion:** 2020-02-05
- **Final completion:** 2020-02-05
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01327612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01327612, "Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01327612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*